X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Panacea Biotech with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs ADCOCK INGRAM (S. Africa) - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PANACEA BIOTECH   ADCOCK INGRAM
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
ADCOCK INGRAM
Jun-14
PANACEA BIOTECH/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs149403-   
Low Rs82291-   
Sales per share (Unadj.) Rs84.1119.9-  
Earnings per share (Unadj.) Rs-18.3-30.2-  
Cash flow per share (Unadj.) Rs-6.7-25.0-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.794.1-  
Shares outstanding (eoy) m61.25168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.42.9 47.4%   
Avg P/E ratio x-6.3-11.5 54.9%  
P/CF ratio (eoy) x-17.2-13.9 124.4%  
Price / Book Value ratio x1.43.7 37.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,07458,557 12.1%   
No. of employees `0002.84.3 64.1%   
Total wages/salary Rs m1,4493,675 39.4%   
Avg. sales/employee Rs Th1,874.14,714.3 39.8%   
Avg. wages/employee Rs Th527.0856.1 61.6%   
Avg. net profit/employee Rs Th-407.7-1,187.9 34.3%   
INCOME DATA
Net Sales Rs m5,15420,238 25.5%  
Other income Rs m100142 70.4%   
Total revenues Rs m5,25420,380 25.8%   
Gross profit Rs m-766-3,507 21.8%  
Depreciation Rs m711873 81.4%   
Interest Rs m1,503548 274.2%   
Profit before tax Rs m-2,881-4,787 60.2%   
Minority Interest Rs m11-13 -80.9%   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m17299 5.6%   
Profit after tax Rs m-1,121-5,100 22.0%  
Gross profit margin %-14.9-17.3 85.8%  
Effective tax rate %-0.6-6.2 9.3%   
Net profit margin %-21.8-25.2 86.3%  
BALANCE SHEET DATA
Current assets Rs m3,81014,823 25.7%   
Current liabilities Rs m8,3658,340 100.3%   
Net working cap to sales %-88.432.0 -275.9%  
Current ratio x0.51.8 25.6%  
Inventory Days Days156111 140.4%  
Debtors Days Days67124 54.2%  
Net fixed assets Rs m14,4808,640 167.6%   
Share capital Rs m6194 65.2%   
"Free" reserves Rs m9030-   
Net worth Rs m5,12715,885 32.3%   
Long term debt Rs m5,8325,582 104.5%   
Total assets Rs m19,43330,008 64.8%  
Interest coverage x-0.9-7.7 11.9%   
Debt to equity ratio x1.10.4 323.7%  
Sales to assets ratio x0.30.7 39.3%   
Return on assets %2.0-15.2 -12.9%  
Return on equity %-21.9-32.1 68.1%  
Return on capital %3.6-19.8 -18.4%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Net fx Rs m5970-   
CASH FLOW
From Operations Rs m5991,727 34.7%  
From Investments Rs m-438-530 82.6%  
From Financial Activity Rs m-3035,066 -6.0%  
Net Cashflow Rs m-1416,263 -2.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.56 Rs / ZAR

Compare PANACEA BIOTECH With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare PANACEA BIOTECH With: ELDER PHARMA  ALEMBIC PHARMA  VENUS REMEDIES  CIPLA  SANOFI INDIA  



Today's Market

Indian Indices Trade Strong; Metal, Pharma Stocks Lead Gains(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading above the dotted line.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 23, 2018 02:11 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - ORCHID PHARMA LTD COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS